Factors associated with discontinuation of treatment for pulmonary arterial hypertension in the United States

Documenti analoghi

• Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension
  di: Charles D. Burger, et al.
  Pubblicazione: (2024)
• Nanoparticle delivery of VEGF and SDF‐1α as an approach for treatment of pulmonary arterial hypertension
  di: Victoria A. Guarino, et al.
  Pubblicazione: (2024)
• Structured evaluation of unclear dyspnea–An attempt to shorten the diagnostic delay in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
  di: Salaheldin Ahmed, et al.
  Pubblicazione: (2024)
• Severe pulmonary hypertension due to combined pulmonary fibrosis and emphysema: another cause of death among smokers
  di: André Carramenha de Góes Hirano
  Pubblicazione: (2017)
• The effects of oxygenation on acute vasodilator challenge in pulmonary arterial hypertension
  di: Matthew D. Rockstrom, et al.
  Pubblicazione: (2024)